Based on these examples, we selected eight potential SNPs in five genes MEG3 (rs10132552T > C), LINC-ROR (rs2027701A > G), pR-lncRNA-1 (rs73594404G > A and rs3743773G > A), LINC-PINT (rs1059698A > C and rs2293750T > A) and TUSC7 (rs1829346C > A and rs36080650T > C) to determine whether genetic polymorphisms of lncRNA-p53 regulatory network genes are associated with toxicities or the therapeutic efficacy of concurrent chemoradiotherapy in NPC in hopes of discovering valuable new biomarkers for personalized CRT among NPC patients. This evidence concerns the gene LINC-ROR and nasopharyngeal carcinoma.